Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.

Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, Andres S, Barbova A, Borbe-Reyes A, Chin DP, Cirillo DM, Colvin C, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Hussain A, Ismail N, Kamal SMM, Khanzada FM, Kimerling M, Kohl TA, Mansjö M, Miotto P, Mukadi YD, Mvusi L, Niemann S, Omar SV, Rigouts L, Schito M, Sela I, Seyfaddinova M, Skenders G, Skrahina A, Tahseen S, Wells WA, Zhurilo A, Weyer K, Floyd K, Raviglione MC.

Lancet Infect Dis. 2018 Jun;18(6):675-683. doi: 10.1016/S1473-3099(18)30073-2. Epub 2018 Mar 21. Erratum in: Lancet Infect Dis. 2018 Mar 27;:.

2.

Alarming levels of multidrug-resistant tuberculosis in Ukraine: results from the first national survey.

Pavlenko E, Barbova A, Hovhannesyan A, Tsenilova Z, Slavuckij A, Shcherbak-Verlan B, Zhurilo A, Vitek E, Skenders G, Sela I, Cabibbe AM, Cirillo DM, de Colombani P, Dara M, Dean A, Zignol M, Dadu A.

Int J Tuberc Lung Dis. 2018 Feb 1;22(2):197-205. doi: 10.5588/ijtld.17.0254.

PMID:
29506617
3.

Determinants of site of tuberculosis disease: An analysis of European surveillance data from 2003 to 2014.

Sotgiu G, Falzon D, Hollo V, Ködmön C, Lefebvre N, Dadu A, van der Werf M.

PLoS One. 2017 Nov 20;12(11):e0186499. doi: 10.1371/journal.pone.0186499. eCollection 2017.

4.

Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience.

Sinkou H, Hurevich H, Rusovich V, Zhylevich L, Falzon D, de Colombani P, Dadu A, Dara M, Story A, Skrahina A.

Eur Respir J. 2017 Mar 22;49(3). pii: 1602049. doi: 10.1183/13993003.02049-2016. Print 2017 Mar. No abstract available.

5.

Policies and practices on the programmatic management of latent tuberculous infection: global survey.

Hamada Y, Sidibe A, Matteelli A, Dadu A, Aziz MA, Del Granado M, Nishikiori N, Floyd K, Getahun H.

Int J Tuberc Lung Dis. 2016 Dec;20(12):1566-1571.

PMID:
27931330
6.

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjö M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC.

Lancet Infect Dis. 2016 Oct;16(10):1185-1192. doi: 10.1016/S1473-3099(16)30190-6. Epub 2016 Jul 7.

7.

Monitoring Therapy Compliance of Tuberculosis Patients by using Video-Enabled Electronic Devices.

Story A, Garfein RS, Hayward A, Rusovich V, Dadu A, Soltan V, Oprunenco A, Collins K, Sarin R, Quraishi S, Sharma M, Migliori GB, Varadarajan M, Falzon D.

Emerg Infect Dis. 2016 Mar;22(3):538-40. doi: 10.3201/eid2203.151620.

8.

Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward.

Acosta CD, Dadu A, Ramsay A, Dara M.

Public Health Action. 2014 Oct 21;4(Suppl 2):S3-S12. doi: 10.5588/pha.14.0087. Review.

9.

First national survey of anti-tuberculosis drug resistance in Azerbaijan and risk factors analysis.

Alikhanova N, Akhundova I, Seyfaddinova M, Mammadbayov E, Mirtskulava V, Rüsch-Gerdes S, Bayramov R, Suleymanova J, Kremer K, Dadu A, Acosta CD, Harries AD, Dara M.

Public Health Action. 2014 Oct 21;4(Suppl 2):S17-23. doi: 10.5588/pha.14.0049.

10.

Factors Associated with Unfavorable Treatment Outcomes in New and Previously Treated TB Patients in Uzbekistan: A Five Year Countrywide Study.

Gadoev J, Asadov D, Tillashaykhov M, Tayler-Smith K, Isaakidis P, Dadu A, de Colombani P, Gudmund Hinderaker S, Parpieva N, Ulmasova D, Jalolov A, Hamraev A, Ali E, Boom Mv, Hammerich A, Gozalov O, Dara M.

PLoS One. 2015 Jun 15;10(6):e0128907. doi: 10.1371/journal.pone.0128907. eCollection 2015.

11.

Towards tuberculosis elimination: an action framework for low-incidence countries.

Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC.

Eur Respir J. 2015 Apr;45(4):928-52. doi: 10.1183/09031936.00214014. Review.

12.

Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data.

Zignol M, Dara M, Dean AS, Falzon D, Dadu A, Kremer K, Hoffmann H, Hoffner S, Floyd K.

Drug Resist Updat. 2013 Dec;16(6):108-15. doi: 10.1016/j.drup.2014.02.003. Epub 2014 Feb 28. Review.

13.

Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011.

Ulmasova DJ, Uzakova G, Tillyashayhov MN, Turaev L, van Gemert W, Hoffmann H, Zignol M, Kremer K, Gombogaram T, Gadoev J, du Cros P, Muslimova N, Jalolov A, Dadu A, de Colombani P, Telnov O, Slizkiy A, Kholikulov B, Dara M, Falzon D.

Euro Surveill. 2013 Oct 17;18(42). pii: 20609.

14.

Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors.

Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, Hoffner S, Rusovich V, Dadu A, de Colombani P, Dara M, van Gemert W, Zignol M.

Bull World Health Organ. 2013 Jan 1;91(1):36-45. doi: 10.2471/BLT.12.104588. Epub 2012 Nov 26.

15.

Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country.

Jenkins HE, Plesca V, Ciobanu A, Crudu V, Galusca I, Soltan V, Serbulenco A, Zignol M, Dadu A, Dara M, Cohen T.

Eur Respir J. 2013 Nov;42(5):1291-301. doi: 10.1183/09031936.00111812. Epub 2012 Oct 25.

16.

Epidemiology of tuberculosis in WHO European Region and public health response.

Dara M, Dadu A, Kremer K, Zaleskis R, Kluge HH.

Eur Spine J. 2013 Jun;22 Suppl 4:549-55. doi: 10.1007/s00586-012-2339-3. Epub 2012 May 8. Review.

17.

Stopping TB in Europe: some progress but still not there.

Falzon D, Kudjawu Y, Desenclos JC, Fernandez de la Hoz K, Dadu A, Zaleskis R.

Euro Surveill. 2008 Mar 18;13(12). pii: 8073. No abstract available.

18.

WHO regional office for Europe: can tuberculosis be contained in the European Region?

Zaleskis R, Ditiu L, de Colombani P, Dadu A; World Health Organization Europe.

Eur J Public Health. 2007 Dec;17(6):668. No abstract available.

PMID:
18083757
19.

Progress toward tuberculosis control and determinants of treatment outcomes--Kazakhstan, 2000-2002.

Bumburidi E, Ajeilat S, Dadu A, Aitmagambetova I, Ershova J, Fagan R, Favorov MO; Centers for Disease Control and Prevention (CDC).

MMWR Suppl. 2006 Apr 28;55(1):11-5.

PMID:
16645576
20.

Hepatitis E virus antibody prevalence among persons who work with swine.

Drobeniuc J, Favorov MO, Shapiro CN, Bell BP, Mast EE, Dadu A, Culver D, Iarovoi P, Robertson BH, Margolis HS.

J Infect Dis. 2001 Dec 15;184(12):1594-7. Epub 2001 Dec 3.

PMID:
11740735

Supplemental Content

Support Center